BG61366B2 - Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания - Google Patents
Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания Download PDFInfo
- Publication number
- BG61366B2 BG61366B2 BG098590A BG9859094A BG61366B2 BG 61366 B2 BG61366 B2 BG 61366B2 BG 098590 A BG098590 A BG 098590A BG 9859094 A BG9859094 A BG 9859094A BG 61366 B2 BG61366 B2 BG 61366B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- compound
- formula
- autoimmune
- preparation
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- -1 1-benzyl-indazol-3-yl Chemical group 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 229960000905 indomethacin Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960005149 bendazac Drugs 0.000 description 2
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001176 lymphocytolytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI911101A IT1253703B (it) | 1991-04-22 | 1991-04-22 | Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG61366B2 true BG61366B2 (bg) | 1997-06-30 |
Family
ID=11359721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG098590A BG61366B2 (bg) | 1991-04-22 | 1994-02-25 | Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5278183A (da) |
| EP (1) | EP0510748B1 (da) |
| JP (1) | JP3056879B2 (da) |
| KR (1) | KR100210199B1 (da) |
| AT (1) | ATE135573T1 (da) |
| AU (1) | AU657524B2 (da) |
| BG (1) | BG61366B2 (da) |
| CA (1) | CA2066304C (da) |
| CZ (1) | CZ280613B6 (da) |
| DE (1) | DE69209128T2 (da) |
| DK (1) | DK0510748T3 (da) |
| IL (1) | IL101660A (da) |
| IT (1) | IT1253703B (da) |
| NZ (1) | NZ242392A (da) |
| SK (1) | SK278546B6 (da) |
| ZA (1) | ZA922740B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2723315B1 (fr) | 1994-08-02 | 1996-10-25 | Cird Galderma | Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes |
| IT1276031B1 (it) * | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | Composizione farmaceutica per il trattamento delle malattie autoimmuni |
| IT1293795B1 (it) * | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| CA2464333C (en) * | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| AU2009221089B2 (en) | 2008-03-07 | 2013-12-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 |
| KR101581829B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| LT2262778T (lt) | 2008-03-07 | 2019-11-11 | Acraf | 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška |
| CN106518769A (zh) | 2009-08-03 | 2017-03-22 | 方济各安吉利克化学联合股份有限公司 | 1‑苄基‑3‑羟甲基‑1h‑吲唑及其衍生物以及所需镁中间体的制备方法 |
| UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1194564B (it) * | 1983-04-18 | 1988-09-22 | Acraf | Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa |
| DE3664036D1 (en) * | 1985-02-12 | 1989-07-27 | Acraf | (1-phenylmethyl-5-hydroxy-1h-indazol-3-yl)-oxyacetic acid and salts thereof for use as a medicament, and pharmaceutical compositions containing them |
| IT1230441B (it) * | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
-
1991
- 1991-04-22 IT ITMI911101A patent/IT1253703B/it active IP Right Grant
-
1992
- 1992-04-11 AT AT92201037T patent/ATE135573T1/de active
- 1992-04-11 DE DE69209128T patent/DE69209128T2/de not_active Expired - Lifetime
- 1992-04-11 EP EP92201037A patent/EP0510748B1/en not_active Expired - Lifetime
- 1992-04-11 DK DK92201037.6T patent/DK0510748T3/da active
- 1992-04-14 US US07/868,311 patent/US5278183A/en not_active Expired - Lifetime
- 1992-04-14 AU AU14883/92A patent/AU657524B2/en not_active Expired
- 1992-04-14 ZA ZA922740A patent/ZA922740B/xx unknown
- 1992-04-16 NZ NZ242392A patent/NZ242392A/en not_active IP Right Cessation
- 1992-04-16 CA CA002066304A patent/CA2066304C/en not_active Expired - Lifetime
- 1992-04-21 IL IL10166092A patent/IL101660A/en not_active IP Right Cessation
- 1992-04-22 CZ CS921227A patent/CZ280613B6/cs not_active IP Right Cessation
- 1992-04-22 KR KR1019920006797A patent/KR100210199B1/ko not_active IP Right Cessation
- 1992-04-22 JP JP4102849A patent/JP3056879B2/ja not_active Expired - Lifetime
- 1992-04-22 SK SK1227-92A patent/SK278546B6/sk not_active IP Right Cessation
-
1994
- 1994-02-25 BG BG098590A patent/BG61366B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0510748A1 (en) | 1992-10-28 |
| JPH0640915A (ja) | 1994-02-15 |
| CA2066304A1 (en) | 1992-10-23 |
| JP3056879B2 (ja) | 2000-06-26 |
| DK0510748T3 (da) | 1996-07-22 |
| DE69209128T2 (de) | 1996-11-28 |
| US5278183A (en) | 1994-01-11 |
| KR920019350A (ko) | 1992-11-19 |
| IT1253703B (it) | 1995-08-23 |
| EP0510748B1 (en) | 1996-03-20 |
| ATE135573T1 (de) | 1996-04-15 |
| ITMI911101A1 (it) | 1992-10-22 |
| CZ280613B6 (cs) | 1996-03-13 |
| IL101660A (en) | 1996-08-04 |
| CS122792A3 (en) | 1992-11-18 |
| KR100210199B1 (ko) | 1999-07-15 |
| SK278546B6 (en) | 1997-09-10 |
| DE69209128D1 (de) | 1996-04-25 |
| CA2066304C (en) | 2005-06-21 |
| ZA922740B (en) | 1992-12-30 |
| ITMI911101A0 (it) | 1991-04-22 |
| AU1488392A (en) | 1992-10-29 |
| AU657524B2 (en) | 1995-03-16 |
| NZ242392A (en) | 1997-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100464693B1 (ko) | 5-메틸이소옥사졸-4-카복실산-(4-트리플루오로메틸)-아닐리드와n-(4-트리플루오로메틸페닐)-2-시아노-3-하이드록시크로톤산아미드와의배합물을함유하는제제 | |
| BG61366B2 (bg) | Използване на съединения на метокси алифатните киселини с индазол за получаване на фармацевтично средство за лечение на автоимунни заболявания | |
| KR20140035538A (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| US20060173011A1 (en) | Treatment of inflammatory disorders with praziquantel | |
| KR20080098494A (ko) | 염증 질환 치료를 위한 ｇａｂａａ-활성화된 신경전달을 증진시키는 화합물의 용도 | |
| KR20010015890A (ko) | 신경변성질환 치료약 | |
| BR112021003563A2 (pt) | composição farmacêutica, método para prevenir ou tratar doenças relacionadas à trombogênese e uso de clopidogrel ou sais | |
| US20050215601A1 (en) | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient | |
| CN1477957A (zh) | 用于治疗高血氨症及肝性脑病的含二氢呋喃环结构的丹参酮类化合物 | |
| KR100365064B1 (ko) | I형알레르기성질환의예방및치료제 | |
| JPS6056920A (ja) | 脂質レベルの低減方法 | |
| Wurtman et al. | Dietary enhancement of CNS neurotransmitters | |
| Pfeiffer et al. | ON THE MECHANISM OF THE NULLIFICATION OF CNS EFFECTS OF l‐DOPA BY PYRIDOXINE IN PARKINSONIAN PATIENTS 1 | |
| RU2160102C2 (ru) | Применение бензидамина для лечения патологических состояний, вызванных фно | |
| US4880803A (en) | Method of inducing immunostimulating activity | |
| US4478845A (en) | Antiinflammatory and/or analgesic imidazoimidazoles | |
| US3906107A (en) | Aminoalkyl sulfate esters with diuretic activity | |
| Austin et al. | Rate of formation of norpethidine from pethidine | |
| EA000166B1 (ru) | Биологически активные уреидо-производные, полезные при лечении рассеянного склероза | |
| US4243673A (en) | Analgesic compositions and methods of use | |
| HU219406B (hu) | Eljárás autoimmun betegségek kezelésére alkalmas, benzil-indazol-származékokat tartalmazó gyógyszerkészítmények előállítására | |
| Beck et al. | Cortical EEG stimulant effects in the rabbit of acetaldehyde-biogenic amine reaction products | |
| JPS62198616A (ja) | 脳血流量改善・脳細胞保護剤 | |
| US4185117A (en) | Method of treatment with glycinamides | |
| Mizutani et al. | Studies on Absorption and Excretion of Drugs. XXIX. Biopharmaceutical Studies on Guaiacol Glycerol Ether and Related Compounds. I. Blood Level of Guaiacol Glycerol Ether in Rabbit and Its Binding with Serum Proteins. |